HomeAdvantage, Powered by Vantive CONNECT
Expanding home therapy possibilities
HomeAdvantage, powered by Vantive CONNECT, powers Vantive’s integrated ecosystem of digitally-enabled PD therapies and services, designed to expand possibilities for home dialysis patients and their care teams.
Intended Use
MyPD Patient Application is intended for use by dialysis patients to receive new or modified treatment parameters from a healthcare professional, to view the collection of treatment data that can be remotely communicated to Sharesource Connectivity Platform and to view their historical treatment results. It is intended for use with commercially available mobile platforms and uses generally available networks and communication protocols.
MyPD Patient Application is not intended to control or perform the treatment of patients undergoing dialysis. This system is not intended to be a substitute for good clinical management practices nor does its operation create decisions or treatment pathways.
The Sharesource Connectivity Platform portal is intended for use by healthcare professionals to remotely communicate new or modified treatment parameters with compatible dialysis instruments and transfer completed treatment data to a central database to aid in the review, analysis, and evaluation of patients’ historical treatment results. This system is not intended to be a substitute for good clinical management practices, nor does its operation create decisions or treatment pathways.
Sharesource Adequest is intended to calculate solute clearances and net fluid removal for individual patients, based on therapy parameters provided by the clinician. Additionally, it is intended to assist the clinician in calculating patient peritoneal membrane transport characteristics and peritoneal dialysis adequacy from data that is inputted into the system by the clinician. The resulting information is used by clinicians in their selection of treatment regimens for individual patients. The calculations can be used for both Continuous Ambulatory PD (CAPD) and Automated PD (APD) patients, and are based on publicly-available information. It is not intended to be a substitute for good clinical management practices, nor does its operation create decisions or treatment pathways. Access the Adequest website to: update your user account information, search for other users at your dialysis center, add Sharesource patients to Adequest, view and enter patient information, 24 hour treatment data and results, PET data and results and generate PD Regimens, Generate reports.
Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.
Vantive, MyPD, Sharesource and Sharesource Adequest are trademarks of Vantive Health LLC or its affiliates.
References
-
Wood E, McCarthy K, Roper M. Remote monitoring of peritoneal dialysis: Evaluating the impact of the Claria Sharesource system. J Kidney Care. 2019;4(1):16-24.
-
Makhija D, Alscher MD, Becker S, et al. Remote monitoring of automated peritoneal dialysis patients: Assessing clinical and economic value. Telemed J E Health. 2018;24(4):315-323.
-
Firanek C, Salas M, Gellens M, Gatesman RD, Wiebenson D, Sloand J. Discrepancy between prescribed and actual APD prescription delivery: Identification using cycler remote management technology. Neph Dial Trans. 2017;32(suppl 3):iii633.
-
Sanabria M, Vesga J, Lindholm B, et al. Time on therapy of automated peritoneal dialysis with and without remote patient monitoring: a cohort study. Int J Nephrol. 2022;Aug 2022:8646775.
-
Todd L, Gellens M, Mooney A, Mancini A. Peritoneal dialysis supplemental telephone support program to reduce 90-day drop out. J Am Soc Nephrol. 2021;32:327-328. Abstract PO0967.
-
Paniagua R, Ramos A, Ávila M, et al. Remote monitoring of automated peritoneal dialysis reduces mortality, adverse events and hospitalizations: a cluster-randomized controlled trial. Nephrol Dial Transplant. 2025;40(3):588-597.